Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GORDON K LAM

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1750427308
CMS profile
124877
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$272,300.21

275 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $68,630.18 81
Janssen Scientific Affairs, LLC $62,066.12 59
Horizon Therapeutics plc $33,505.60 37
AstraZeneca Pharmaceuticals LP $32,820.20 29
GlaxoSmithKline, LLC. $31,376.31 23
E.R. Squibb & Sons, L.L.C. $17,738.57 13
GENZYME CORPORATION $8,242.91 6
UCB, Inc. $8,063.82 7
PFIZER INC. $4,914.75 3
Janssen Biotech, Inc. $4,658.22 6
Aurinia Pharma U.S., Inc. $138.10 2
Amgen Inc. $70.68 4
Novartis Pharmaceuticals Corporation $39.04 2
Lilly USA, LLC $13.41 1
Merck Sharp & Dohme Corporation $11.15 1
Organon LLC $11.15 1

Page 2 of 6; records 51–100 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GORDON K LAM

NPI 1750427308 · CMS profile ID 124877

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750427308?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GORDON K LAM, NPI 1750427308, CMS profile ID 124877. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750427308?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GORDON K LAM, NPI 1750427308, CMS profile ID 124877. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750427308?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GORDON K LAM, NPI 1750427308, CMS profile ID 124877, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750427308?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

275 matching records · $272,300.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 275 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 275.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $4,300.0011/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829342107 CMS
Janssen Scientific Affairs, LLC $114.1411/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640993 CMS
Janssen Scientific Affairs, LLC $924.3711/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640995 CMS
Horizon Therapeutics plc $1,350.0011/15/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162853 CMS
GlaxoSmithKline, LLC. $124.7411/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802869571 CMS
GlaxoSmithKline, LLC. $957.8311/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802914121 CMS
AbbVie Inc. $1,575.0011/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208669 CMS
Amgen Inc. $17.0811/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825336263 CMS
Amgen Inc. $16.0811/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825336275 CMS
GlaxoSmithKline, LLC. $39.7211/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802427053 CMS
E.R. Squibb & Sons, L.L.C. $2,310.0011/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783439583 CMS
Horizon Therapeutics plc $450.0011/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162851 CMS
Janssen Scientific Affairs, LLC $38.6411/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640991 CMS
AstraZeneca Pharmaceuticals LP $3,200.0011/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829888209 CMS
Janssen Biotech, Inc. $1,250.0011/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640883 CMS
AbbVie Inc. $28.5210/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208663 CMS
AstraZeneca Pharmaceuticals LP $31.3710/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830104283 CMS
AstraZeneca Pharmaceuticals LP $788.8410/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830157271 CMS
GlaxoSmithKline, LLC. $58.0010/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802928831 CMS
Horizon Therapeutics plc $1,350.0010/26/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162849 CMS
AbbVie Inc. $2,625.0010/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208657 CMS
Janssen Scientific Affairs, LLC $1,000.0010/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640981 CMS
Janssen Scientific Affairs, LLC $2,250.0010/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640989 CMS
Janssen Scientific Affairs, LLC $73.6610/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640987 CMS
AbbVie Inc. $99.9410/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208651 CMS
GlaxoSmithKline, LLC. $3,600.0010/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802942025 CMS
GlaxoSmithKline, LLC. $3,600.0010/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803180345 CMS
Novartis Pharmaceuticals Corporation $19.4810/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813009663 CMS
GlaxoSmithKline, LLC. $3,600.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802405077 CMS
AstraZeneca Pharmaceuticals LP $71.8510/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829356815 CMS
AstraZeneca Pharmaceuticals LP $38.6410/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829372267 CMS
UCB, Inc. $1,150.0010/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807421739 CMS
Janssen Scientific Affairs, LLC $1,000.0010/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640979 CMS
AbbVie Inc. $19.9810/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208647 CMS
Horizon Therapeutics plc $450.0010/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162847 CMS
PFIZER INC. $2,700.0010/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833394159 CMS
AbbVie Inc. $38.6409/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208641 CMS
GlaxoSmithKline, LLC. $109.9809/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802338495 CMS
GlaxoSmithKline, LLC. $1,069.9309/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802917515 CMS
Janssen Scientific Affairs, LLC $1,000.0009/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788640977 CMS
AbbVie Inc. $1,575.0009/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208629 CMS
AbbVie Inc. $2,625.0009/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208635 CMS
GlaxoSmithKline, LLC. $108.1109/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801721459 CMS
GlaxoSmithKline, LLC. $1,200.0009/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803041771 CMS
AbbVie Inc. $72.0909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208623 CMS
GENZYME CORPORATION $15.9109/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843586963 CMS
AstraZeneca Pharmaceuticals LP $3,200.0009/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829530125 CMS
AbbVie Inc. $1,575.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795208617 CMS
AstraZeneca Pharmaceuticals LP $1,050.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830106561 CMS
AstraZeneca Pharmaceuticals LP $125.0008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829388527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $473,736.63 524
PY2020 $306,448.14 269
PY2021 $272,300.21 275
PY2022 $417,636.08 430
PY2023 $409,242.90 485
PY2024 $399,439.35 493
PY2025 $436,286.11 507

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,817.22 28
PY2024 Recipient $517.64 2
PY2024 Principal investigator $169,302.12 13
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $45,050.20 8
PY2022 Principal investigator $6,512.50 2
PY2021 Principal investigator $4,770.00 2
PY2020 Recipient $56.00 2
PY2020 Principal investigator $19,615.00 13
PY2019 Recipient $1,073.90 3
PY2019 Principal investigator $21,631.00 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,613.00 12/11/2025 Non-covered Recipient Entity
Arthritis & Osteoporosis Consultants Of The Carolinas
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) No dispute reported 06/30/2026 1235998900
Principal investigator 1 GlaxoSmithKline, LLC. $5,063.75 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
THE EVALUATION OF USE OF BELIMUMAB IN ROUTINE CARE SETTINGS IN LUPUS N No dispute reported 06/30/2026 1192169360
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,471.51 11/10/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190312521
Principal investigator 1 GlaxoSmithKline, LLC. $4,743.00 11/05/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192170615
Principal investigator 1 GlaxoSmithKline, LLC. $2,418.30 10/02/2025 Non-covered Recipient Entity
ARTHRITIS OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169369
Principal investigator 1 GlaxoSmithKline, LLC. $3,102.30 09/03/2025 Non-covered Recipient Entity
ARTHRITIS OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169356
Principal investigator 1 SANOFI US SERVICES INC. $200.00 09/03/2025 Non-covered Recipient Entity
Arthritis And Osteoporosis Consulta Of The Carolinas
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226148731
Principal investigator 1 Amgen Inc. $6,675.00 08/16/2025 Non-covered Recipient Entity
ATRIUM HEALTH CABARRUS
Ph 4 Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA No dispute reported 06/30/2026 1246639475
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,500.00 08/13/2025 Non-covered Recipient Entity
Arthritis & Osteoporosis Consultants of California
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931298
Principal investigator 1 GlaxoSmithKline, LLC. $6,217.20 08/01/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169387
Principal investigator 1 GlaxoSmithKline, LLC. $6,217.20 07/02/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169373
Principal investigator 1 SANOFI US SERVICES INC. $19,561.40 07/02/2025 Non-covered Recipient Entity
Arthritis And Osteoporosis Consulta Of The Carolinas
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226148702
Principal investigator 1 Amgen Inc. $9,000.00 06/06/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639391
Principal investigator 1 GlaxoSmithKline, LLC. $10,971.00 06/04/2025 Non-covered Recipient Entity
ARTHRITIS OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192167044
Principal investigator 1 SANOFI US SERVICES INC. $23,094.00 05/19/2025 Non-covered Recipient Entity
Arthritis And Osteoporosis Consulta Of The Carolinas
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226148691
Principal investigator 1 SANOFI US SERVICES INC. $5,274.10 05/19/2025 Non-covered Recipient Entity
Arthritis And Osteoporosis Consulta Of The Carolinas
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226148695
Principal investigator 1 GlaxoSmithKline, LLC. $7,868.70 05/09/2025 Non-covered Recipient Entity
ARTHRITIS OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169377
Principal investigator 1 GlaxoSmithKline, LLC. $2,418.30 04/02/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192170611
Principal investigator 1 Aurinia Pharma U.S., Inc. $9,525.00 03/12/2025 Non-covered Recipient Entity
Arthritis & Osteoporosis Consultants of California
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930894
Principal investigator 1 GlaxoSmithKline, LLC. $2,418.30 03/07/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169364
Principal investigator 1 GlaxoSmithKline, LLC. $2,745.00 02/27/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
THE EVALUATION OF USE OF BELIMUMAB IN ROUTINE CARE SETTINGS IN LUPUS N No dispute reported 06/30/2026 1192167048
Principal investigator 1 AstraZeneca UK Limited $101,396.00 02/06/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185546403
Principal investigator 1 GlaxoSmithKline, LLC. $11,910.00 02/05/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192169383
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 02/05/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190312519
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,408.51 01/30/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190312523
Principal investigator 1 Amgen Inc. $197,001.13 01/21/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639393
Principal investigator 1 Novartis Pharmaceuticals Corporation $48.12 01/15/2025 Non-covered Recipient Entity
ARTHRITIS AND OSTEOPOROSIS MEDICAL ASSOC
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190308840
Principal investigator 1 SANOFI US SERVICES INC. $12,956.40 01/13/2025 Non-covered Recipient Entity
Arthritis And Osteoporosis Consulta Of The Carolinas
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226148670